The WHO Programme for International Drug Monitoring

Pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem.

The aims of PV are to enhance patient care and patient safety in relation to the use of medicinal products; and to support public health programmes by providing reliable, balanced information to assess the risk-benefit profile of medicines.

In 1963, during the 16th World Health Assembly, resolution 16.36 called for “a systematic collection of information on serious adverse drug reactions during the development and particularly after medicines have been made available for public use”. This led to the formation of the WHO Programme for International Drug Monitoring (PIDM) in 1968.

WHO PIDM Members submit reports of adverse reactions associated with medicinal products, known as Individual Case Safety Reports (ICSRs) to the WHO global database, VigiBaseVigiBase is managed and maintained by the WHO Collaborating Centre for International Drug Monitoring, known as Uppsala Monitoring Centre. In July 2023, there were over 35 million reports of adverse reactions in VigiBase. Data in VigiBase are recorded in a structured and comprehensive way to allow the detection of potential medicinal safety hazards.

In April 2015, WHO launched VigiAccess. VigiAccess is a new web application that will allow anyone to access information and encourage the reporting of adverse effects from medicinal products.

New Members of the WHO Programme for International Drug Monitoring

PIDM_20241127

We have welcomed Sao Tome and Principe as full member of our big family of pharmacovigilance (medicine & vaccine safety), the WHO Programme for International Drug Monitoring (PIDM), following their successful safety reports sharing with the WHO VigiBase. The WHO PIDM has now 160 full members & 22 associate members. Information as of 21 March 2025.

Map showing the members of the WHO PIDM as of March 2025. Green: Full member; Orange: Associate member; Blue: Non-member.

Full and associate members of the WHO PIDM (year they joined)

Full member countries (160)

WHO member states

Afghanistan (2016)
Albania (2020)
Algeria (2021)
Andorra (2008)
Angola (2013) 
Argentina (1994) 
Armenia (2001) 
Australia (1968) 
Austria (1991)
Azerbaijan (2018)

Bangladesh (2014)
Barbados (2008)
Belarus (2006)  
Belgium (1977)
Benin (2011)
Bhutan (2014)
Bolivia (Plurinational State of) (2013)
Bosnia and Herzegovina (2019)
Botswana (2009)  
Brazil (2001) 
Brunei Darussalam (2005)    
Bulgaria (1975) 
Burkina Faso (2010)

Burundi (2022)


Cabo Verde (2012)
Cambodia (2012)
Cameroon (2010) 
Canada (1968)

Central African Republic (2022) 

Chad (2018)
Chile (1996) 
China (1998) 
Colombia (2004)
Congo (2021) 
Costa Rica (1991) 
Côte d'Ivoire (2010) 

Croatia (1992) 
Cuba (1994) 
Cyprus (2000) 
Czechia (1992) 

Democratic Republic of the Congo (2010)
Denmark (1971)
Dominican Republic (2020) 

 

Ecuador (2017)
Egypt (2001)
El Salvador (2017)
Eritrea (2012) 
Estonia (1998) 
Eswatini (2015)
Ethiopia (2008) 

Fiji (1999) 
Finland (1974) 
France (1986)

Gabon (2023)

Gambia (2021)
Georgia (2018)
Germany (1968) 
Ghana (2001) 
Greece (1990) 
Guatemala (2002)
Guinea (2013)

Guinea-Bissau (2022)

 

Honduras (2020)
Hungary (1990)

Iceland (1990)
India (1998) 
Indonesia (1990) 
Iran (Islamic Republic of) (1998) 
Iraq (2010) 
Ireland (1968) 
Israel (1973)
Italy (1975)

Jamaica (2012)
Japan (1972) 
Jordan (2002)

Kazakhstan (2008) 
Kenya (2010)
Kuwait (2021) 
Kyrgyzstan (2003)

Lao People’s Democratic Republic (2015)
Latvia (2002)
Lebanon (2021)

Lesotho (2024)

Liberia (2013)
Libya (2021)
Lithuania (2005)
Luxembourg (2020) 

Madagascar (2009) 
Malawi (2019)
Malaysia (1990)
Maldives (2016) 
Mali (2011)
Malta (2004)

Mauritania (2023)

Mauritius (2014) 
Mexico (1999) 

Mongolia (2021)

Montenegro (2009) 
Morocco (1992) 
Mozambique (2005)

Namibia (2008)   
Nepal (2006) 
Netherlands (1968) 
New Zealand (1968) 
Nicaragua (2020)
Niger (2012)
Nigeria (2004)
North Macedonia (2000) 
Norway (1971)

Oman (1995)

Pakistan (2018)
Panama (2016)
Papua New Guinea (2018)
Paraguay (2018)
Peru (2002) 
Philippines (1995) 
Poland (1972) 
Portugal (1993)

 

Republic of Korea (1992)
Republic of Moldova (2003)
Romania (1976) 
Russian Federation (1998)
Rwanda (2013)

 

Saint Vincent and the Grenadines (2020) 

Sao Tome and Principe (2025)

Saudi Arabia (2009) 
Senegal (2009)  
Serbia (2000) 
Sierra Leone (2008)  
Singapore (1993) 
Slovakia (1993) 
Slovenia (2010)  
South Africa (1992) 

South Sudan (2024)

Spain (1984) 
Sri Lanka (2000) 
Sudan (2008) 
Suriname (2007) 
Sweden (1968) 
Switzerland (1991)
Syrian Arab Republic (2018)

Tajikistan (2023)
Thailand (1984) 
Togo (2007) 
Tunisia (1993) 
Türkiye (1987)

Uganda (2007) 
Ukraine (2002) 
United Arab Emirates (2013)
United Kingdom of Great Britain and Northern Ireland (1968) 
United Republic of Tanzania

Mainland (1993)

Zanzibar (2024)

United States of America (1968)
Uruguay (2001) 
Uzbekistan (2006)
 
Venezuela (Bolivarian Republic of) (1995) 
Viet Nam (1999)

Yemen (2022)

Zambia (2010)  
Zimbabwe (1998)

 

Associate members (22)

WHO member states

Antigua and Barbuda

 

Bahamas
Bahrain
Belize 

 

Comoros

Cook Islands

 

Djibouti

Dominica

Equatorial Guinea

Grenada

Guyana

 

Haiti

 

 

 

Myanmar 

Qatar

Saint Kitts and Nevis
Saint Lucia

Seychelles

Somalia

Timor-Leste

Territories /Areas

Anguilla
British Virgin Islands
Montserrat

Recommendations

The working group discussed the scope and limits of pharmacovigilance (PV) centres in preventing medication errors and how PV centres can have proactive...

The working group discussed the scope and limits of pharmacovigilance (PV) centres in preventing medication errors and how PV centres can have proactive...

The working group discussed the scope and limits of pharmacovigilance (PV) centres in preventing medication errors and how PV centres can have proactive...

The working group discussed the scope and limits of pharmacovigilance (PV) centres in preventing medication errors and how PV centres can have proactive...

The working group discussed the scope and limits of pharmacovigilance (PV) centres in preventing medication errors and how PV centres can have proactive...

The working group discussed the scope and limits of pharmacovigilance (PV) centres in preventing medication errors and how PV centres can have proactive...

The working group discussed the scope and limits of pharmacovigilance (PV) centres in preventing medication errors and how PV centres can have proactive...

The working group discussed the scope and limits of pharmacovigilance (PV) centres in preventing medication errors and how PV centres can have proactive...